- Home
- MTR vs MRKR Comparison
MTR vs MRKR Comparison
Compare MTR & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- MRKR
- Stock Information
- Founded
- MTR 1979
- MRKR N/A
- Country
- MTR United States
- MRKR United States
- Employees
- MTR N/A
- MRKR N/A
- Industry
- MTR Oil & Gas Production
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- MTR Energy
- MRKR Health Care
- Exchange
- MTR Nasdaq
- MRKR Nasdaq
- Market Cap
- MTR 10.6M
- MRKR 11.6M
- IPO Year
- MTR N/A
- MRKR N/A
- Fundamental
- Price
- MTR N/A
- MRKR $1.08
- Analyst Decision
- MTR
- MRKR Strong Buy
- Analyst Count
- MTR 0
- MRKR 3
- Target Price
- MTR N/A
- MRKR $13.17
- AVG Volume (30 Days)
- MTR 2.8K
- MRKR 312.6K
- Earning Date
- MTR 01-01-0001
- MRKR 11-13-2025
- Dividend Yield
- MTR 3.24%
- MRKR N/A
- EPS Growth
- MTR N/A
- MRKR N/A
- EPS
- MTR 0.21
- MRKR N/A
- Revenue
- MTR $580,337.00
- MRKR $5,388,071.00
- Revenue This Year
- MTR N/A
- MRKR N/A
- Revenue Next Year
- MTR N/A
- MRKR $9.35
- P/E Ratio
- MTR $24.12
- MRKR N/A
- Revenue Growth
- MTR N/A
- MRKR 44.55
- 52 Week Low
- MTR $4.70
- MRKR $0.81
- 52 Week High
- MTR $10.42
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- MTR 32.96
- MRKR 54.04
- Support Level
- MTR $5.12
- MRKR $0.85
- Resistance Level
- MTR $5.34
- MRKR $1.13
- Average True Range (ATR)
- MTR 0.14
- MRKR 0.07
- MACD
- MTR -0.05
- MRKR 0.03
- Stochastic Oscillator
- MTR 0.00
- MRKR 64.29
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.